Cleveland BioLabs, Inc

(NASDAQ:CBLI)

Latest On Cleveland BioLabs, Inc (CBLI):

Date/Time Type Description Signal Details
2021-09-01 01:03 ESTNewsCytocom to rename as Statera BioPharmaN/A
2021-08-16 15:09 ESTNewsCleveland BioLabs reports Q2 resultsN/A
2021-08-16 15:08 ESTNewsCytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-29 15:37 ESTNewsCytocom secures $90M in debt and equity financingN/A
2021-07-20 23:41 ESTNewsCleveland Bio pops 4% after SEC declared effectiveness of registration statementN/A
2021-02-20 00:37 ESTNewsCleveland BioLabs readies $14M stock offeringN/A
2021-02-18 12:13 ESTNewsCleveland Bio files Form S-4 for Cytocom merger, shares up 27%N/A
2021-02-17 00:58 ESTNewsICON partners with Cytocom in a Phase 3 trial for Crohn's diseaseN/A
2020-12-13 03:27 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 19:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-15 11:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 17:27 ESTFinancialsCompany financials have been released.Neutral
2020-10-20 17:14 ESTNewsCleveland BioLabs up 66% on planned merger with CytocomN/A
2020-09-24 00:23 ESTFinancialsCompany financials have been released.Neutral
2020-09-19 08:27 ESTFinancialsCompany financials have been released.Neutral
2020-08-16 12:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:31 ESTFinancialsCompany financials have been released.Neutral
2020-07-10 08:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 08:17 ESTFinancialsCompany financials have been released.Neutral
2020-06-27 14:49 ESTNewsCleveland BioLabs joins COVID vaccine-stoked rallyN/A
2020-06-01 20:56 ESTNewsCleveland Biolabs -11.7% on $3.175M registered direct offeringN/A
2020-05-31 16:49 ESTFinancialsCompany financials have been released.Neutral
2020-05-23 01:09 ESTNewsCleveland BioLabs files for $50M mixed shelfN/A
2020-05-20 12:27 ESTFinancialsCompany financials have been released.Neutral
2020-05-16 20:41 ESTNewsCleveland BioLabs reports Q1 resultsN/A
2020-05-03 08:24 ESTFinancialsCompany financials have been released.Neutral
2020-04-18 00:18 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 06:48 ESTNewsCoronavirus death toll jumps in ChinaN/A
2020-04-11 06:34 ESTNewsCoronavirus plays - vaccines, drugs & infection control productsN/A
2020-04-11 06:26 ESTNewsFamiliar names gain as COVID-19 weighs on marketN/A
2020-04-11 04:16 ESTStock SplitA stock split has occured on Jan 28, 2015 with a split factor of 1:20.Neutral
2020-04-09 12:19 ESTFinancialsCompany financials have been released.Neutral
2020-04-07 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 23:20 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 03:22 ESTFinancialsCompany financials have been released.Neutral
2020-02-21 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-02-06 23:18 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 23:19 ESTFinancialsCompany financials have been released.Neutral
2020-01-27 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-01-15 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-12-16 23:18 ESTFinancialsCompany financials have been released.Neutral
2019-11-27 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-11-26 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-11-22 23:15 ESTFinancialsCompany financials have been released.Neutral
2019-11-18 23:12 ESTFinancialsCompany financials have been released.Neutral
2019-11-15 23:16 ESTFinancialsCompany financials have been released.Neutral
2019-11-14 16:55 ESTNewsCleveland BioLabs reports Q3 resultsN/A
2019-11-12 09:11 ESTNewsCleveland BioLabs: Another Year - Only Cash Burn To ShowN/A
2019-11-06 23:16 ESTFinancialsCompany financials have been released.Neutral

About Cleveland BioLabs, Inc (CBLI):

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.

CBLI Quotes by TradingView

See Advanced Chart

General

  • Name Cleveland BioLabs, Inc
  • Symbol CBLI
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 7
  • Last Split Factor1:20
  • Last Split Date2015-01-28
  • Fiscal Year EndDecember
  • IPO Date2006-07-21
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.cbiolabs.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 109.07
  • Enterprise Value Revenue 136.1
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Operating Margin -331%
  • Return on Assets -48%
  • Return on Equity -110%
  • Revenue 631842
  • Earnings Per Share -$0.27
  • Revenue Per Share $0.05
  • Gross Profit -543006
  • Quarterly Earnings Growth -83.8%
View More

Highlights

  • Market Capitalization 99.48 million
  • EBITDA -3441400
  • PE Ratio -18.6
  • Analyst Target Price $2
  • Book Value Per Share -$0.26
View More

Share Statistics

  • Shares Outstanding 15.38 million
  • Shares Float 6.59 million
  • % Held by Insiders 5641%
  • % Held by Institutions 6.67%
  • Shares Short 18008
  • Shares Short Prior Month 53219
  • Short Ratio 0.03
View More

Technicals

  • Beta 0.59
  • 52 Week High $9.53
  • 52 Week Low $1.27
  • 50 Day Moving Average 6.21
  • 200 Day Moving Average 3.68
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cleveland BioLabs, Inc (CBLI) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cleveland BioLabs, Inc (CBLI) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-17$N/A-$0.06
2020-06-302020-09-30$N/A-$0.06
2020-03-312020-06-30$156042-$0.03
2019-12-312020-03-31$368900-$0.05
2019-09-302019-12-31$269635-$0.06
2019-06-302019-09-30$276967-$0.04
2019-03-312019-06-30$197919-$0.05
2018-12-312019-03-31$235713-$0.08
2018-09-302018-12-31$283307-$0.04
2018-06-302018-09-30$391591-$0.10
2018-03-312018-06-30$227576-$0.08
2017-12-312018-03-31$870000-$0.11
2017-09-302017-12-31$297000-$0.10
2017-06-302017-09-30$206000-$0.11
2017-03-312017-06-30$575000-$0.50
2016-12-312017-03-31$989000-$0.15
2016-09-302016-12-31$1.14 million-$0.11
2016-06-302016-09-30$575000$0.10
2016-03-312016-06-30$813000-$0.17
2015-12-312016-03-31$1.27 million-$0.06
2015-09-302015-12-31$502000-$0.13
2015-06-302015-09-30$330000-$0.31
2015-03-312015-06-30$607000-$1.12
2014-12-312015-03-31$1.39 million-$1.14
2014-09-302014-12-31$415000$3.95
2014-06-302014-09-30$562000-$1.43
2014-03-312014-06-30$1.33 million-$1.53-$1.00-52.67%
2013-12-312014-03-31$3.87 million-$0.63-$2.4073.56%
2013-09-302013-12-31$1.64 million-$0.16-$2.7094.01%
2013-06-302013-09-30$1.61 million-$1.82-$3.1041.43%
2013-03-312013-06-30$1.37 million-$1.35-$3.4060.19%
2012-12-312013-03-31$2.16 million-$4.36-$4.20-3.73%
2012-09-302012-12-31$219000$1.46
2012-06-302012-09-30$259000-$6.06-$0.80-657.95%
2012-03-312012-06-30$931000-$2.84-$2.902.01%
2011-12-312012-03-31$1.95 million-$3.02-$2.60-16.22%
2011-09-302011-12-31$3.8 million-$4.12-$2.80-47.05%
2011-06-302011-09-30$569000-$1.60-$2.6038.46%
2011-03-312011-06-30$2.47 million$6.00-$0.203100%
2010-12-312011-03-31$3.76 million-$3.78-$1.60-136.13%
2010-09-302010-12-31$3.19 million-$9.73-$2.20-342.1%
2010-06-302010-08-16$4.21 million-$1.80-$1.800%
2010-03-312010-05-14$4.17 million-$2.80-$2.20-27.27%
2009-12-312010-03-22$4.63 million$1.20-$1.60175%
2009-09-302009-11-12$3.22 million-$6.60-$1.80-266.67%
2009-06-302009-08-13$4.19 million-$9.06
2009-03-312009-05-13$2.31 million-$4.74
2008-12-312009-03-30$1.5 million-$5.40-$4.20-28.57%
2008-09-302008-11-14$1.85 million-$4.60-$4.600%
2008-06-302008-08-12$675000-$6.00-$4.60-30.43%
2008-03-312008-05-14$676000-$6.60-$17.6062.5%
2007-12-312008-03-21$401000-$15.40-$8.80-75%
2007-09-302007-11-14$661000-$10.80-$6.20-74.19%
2007-06-302007-08-14$636000-$12.80-$5.20-146.15%
2007-03-312007-05-15$321000-$7.00-$4.40-59.09%
2006-12-312007-03-29$231000-$6.97
2006-09-302006-11-13$324000-$3.01
2006-06-302006-08-25$575000-$4.21

Cleveland BioLabs, Inc (CBLI) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 218208 281018 262410
Income Before Tax N/A N/A -601728 -700391 -467367
Selling General Administrative N/A N/A 382166 368549 525621
Gross Profit N/A N/A N/A N/A 269635
Ebit N/A N/A -441252 -277188 -518396
Operating Income N/A N/A -444332 -280667 -518396
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A 156042 368900 269635
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A -160296 17526 51029
Net Income From Continuing Operations N/A N/A -601728 -700391 -467367
Net Income Applicable to Common Shares -745388 -369838 N/A -707297 -449919
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A -1761 -37795
Change to Liabilities -34940 -23957 N/A 503022 -339952
Total Cash Flow from Investing Activities -858 43245 N/A -1761 -31745
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 382215 N/A N/A
Change to Operating Activities N/A 18667 N/A 13 9
Change in Cash N/A N/A -67313 -361264 -750429
Total Cash from Operating Activities -682657 -476411 -425593 -364454 -713040
Depreciation N/A N/A 3080 3479 2774
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A 8074 -145630 134077
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income -17411 -216214 N/A -18041 -60029
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 1.09 million 1.05 million 565682
Total Stockholder Equity N/A N/A -4.21 million -4.06 million -3.36 million
Other Current Liabilities 15432 N/A N/A N/A 24461
Total Assets N/A N/A 1.86 million 2.04 million 2.23 million
Common Stock 65077 64163 N/A 56487 56487
Other Current Assets 54862 N/A 80028 45381 67552
Retained Earnings -168.41 million -167.66 million -167.29 million -166.71 million -166 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A 18667 18667
Cash N/A N/A 1.06 million 1.13 million 1.49 million
Total Current Liabilities 483873 N/A 1.09 million 1.05 million 565682
Other Stockholder Equity -645022 -612124 N/A -568030 -582904
Property, Plant & Equipment 6369 9233 N/A 15514 17445
Total Current Assets 3.22 million N/A 1.83 million 2 million 2.19 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets -2.22 million -1.71 million N/A -4.06 million -3.36 million
Short Term Investments N/A N/A 360210 452301 426915
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 280559 N/A 266058 263573 99529

Cleveland BioLabs, Inc (CBLI) Chart:

Cleveland BioLabs, Inc (CBLI) News:

Below you will find a list of latest news for Cleveland BioLabs, Inc (CBLI) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cleveland BioLabs, Inc (CBLI) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Cleveland BioLabs, Inc (CBLI) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000091957420004035/0000919574-20-004035-index.htm
2016-02-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1318641/000000000016065068/0000000000-16-065068-index.htm
2020-05-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1318641/000000000020004708/0000000000-20-004708-index.htm
2020-06-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000091957420004035/0000919574-20-004035-index.htm
2020-01-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000094078020000005/0000940780-20-000005-index.htm
2016-01-29S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1318641/000121390016010481/0001213900-16-010481-index.htm
2016-02-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016010580/0001213900-16-010580-index.htm
2016-03-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1318641/000121390016011315/0001213900-16-011315-index.htm
2016-03-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1318641/000121390016011630/0001213900-16-011630-index.htm
2016-03-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1318641/000121390016011763/0001213900-16-011763-index.htm
2016-05-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016013209/0001213900-16-013209-index.htm
2016-05-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016013586/0001213900-16-013586-index.htm
2016-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016015364/0001213900-16-015364-index.htm
2016-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016015366/0001213900-16-015366-index.htm
2016-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016015368/0001213900-16-015368-index.htm
2018-02-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000121390018002383/0001213900-18-002383-index.htm
2018-08-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390018011138/0001213900-18-011138-index.htm
2016-02-18PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000004/0001318641-16-000004-index.htm
2016-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000006/0001318641-16-000006-index.htm
2016-02-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000009/0001318641-16-000009-index.htm
2016-03-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000012/0001318641-16-000012-index.htm
2016-03-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000014/0001318641-16-000014-index.htm
2016-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000016/0001318641-16-000016-index.htm
2016-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000018/0001318641-16-000018-index.htm
2016-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000020/0001318641-16-000020-index.htm
2016-05-1610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000023/0001318641-16-000023-index.htm
2016-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000029/0001318641-16-000029-index.htm
2016-07-218-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000031/0001318641-16-000031-index.htm
2016-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000034/0001318641-16-000034-index.htm
2016-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000036/0001318641-16-000036-index.htm
2016-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000040/0001318641-16-000040-index.htm
2016-08-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000041/0001318641-16-000041-index.htm
2016-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000043/0001318641-16-000043-index.htm
2016-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000046/0001318641-16-000046-index.htm
2016-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000047/0001318641-16-000047-index.htm
2017-02-21PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000007/0001318641-17-000007-index.htm
2017-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000010/0001318641-17-000010-index.htm
2017-02-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000012/0001318641-17-000012-index.htm
2017-03-03DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000016/0001318641-17-000016-index.htm
2017-03-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000018/0001318641-17-000018-index.htm
2017-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000020/0001318641-17-000020-index.htm
2017-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000024/0001318641-17-000024-index.htm
2017-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000027/0001318641-17-000027-index.htm
2017-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000028/0001318641-17-000028-index.htm
2017-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000031/0001318641-17-000031-index.htm
2017-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000037/0001318641-17-000037-index.htm
2017-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000039/0001318641-17-000039-index.htm
2017-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000043/0001318641-17-000043-index.htm
2017-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000045/0001318641-17-000045-index.htm
2018-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000005/0001318641-18-000005-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000007/0001318641-18-000007-index.htm
2018-03-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000010/0001318641-18-000010-index.htm
2018-03-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000011/0001318641-18-000011-index.htm
2018-03-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000013/0001318641-18-000013-index.htm
2018-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000015/0001318641-18-000015-index.htm
2018-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000017/0001318641-18-000017-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000021/0001318641-18-000021-index.htm
2018-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000023/0001318641-18-000023-index.htm
2018-06-19S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000025/0001318641-18-000025-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000027/0001318641-18-000027-index.htm
2018-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000029/0001318641-18-000029-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000036/0001318641-18-000036-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000037/0001318641-18-000037-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000038/0001318641-18-000038-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000042/0001318641-18-000042-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000043/0001318641-18-000043-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864119000005/0001318641-19-000005-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000007/0001318641-19-000007-index.htm
2019-03-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000010/0001318641-19-000010-index.htm
2019-03-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000011/0001318641-19-000011-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000013/0001318641-19-000013-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000018/0001318641-19-000018-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864119000019/0001318641-19-000019-index.htm
2019-05-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000021/0001318641-19-000021-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000024/0001318641-19-000024-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864119000025/0001318641-19-000025-index.htm
2019-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000027/0001318641-19-000027-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919020455/0001437749-19-020455-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919022930/0001437749-19-022930-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000143774919022938/0001437749-19-022938-index.htm
2019-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919023068/0001437749-19-023068-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919023806/0001437749-19-023806-index.htm
2019-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919024606/0001437749-19-024606-index.htm
2019-12-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000143774919024826/0001437749-19-024826-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920003393/0001437749-20-003393-index.htm
2020-03-31NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1318641/000143774920006663/0001437749-20-006663-index.htm
2020-04-1510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000143774920007716/0001437749-20-007716-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000143774920008857/0001437749-20-008857-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920009193/0001437749-20-009193-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920010885/0001437749-20-010885-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920010888/0001437749-20-010888-index.htm
2020-05-21S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1318641/000143774920011586/0001437749-20-011586-index.htm
2020-05-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1318641/000143774920011817/0001437749-20-011817-index.htm
2020-05-29424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920012078/0001437749-20-012078-index.htm
2020-06-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920012249/0001437749-20-012249-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920012341/0001437749-20-012341-index.htm
2020-06-04DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920012488/0001437749-20-012488-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920016187/0001437749-20-016187-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920017908/0001437749-20-017908-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920017915/0001437749-20-017915-index.htm
2020-08-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920018563/0001437749-20-018563-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021047/0001437749-20-021047-index.htm
2020-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021282/0001437749-20-021282-index.htm
2020-10-19425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021283/0001437749-20-021283-index.htm
2020-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021417/0001437749-20-021417-index.htm
2020-10-21425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021418/0001437749-20-021418-index.htm
2020-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021867/0001437749-20-021867-index.htm
2020-10-28425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021868/0001437749-20-021868-index.htm
2020-11-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920023024/0001437749-20-023024-index.htm
2020-11-06DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000143774920023025/0001437749-20-023025-index.htm
2016-01-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000153561016000090/0001535610-16-000090-index.htm
2018-01-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000153561018000008/0001535610-18-000008-index.htm
2017-05-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000170467317000002/0001704673-17-000002-index.htm
2016-03-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1318641/999999999516003992/9999999995-16-003992-index.htm
2020-05-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1318641/999999999520001291/9999999995-20-001291-index.htm
2016-11-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1318641/999999999716027089/9999999997-16-027089-index.htm
2017-11-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1318641/999999999717009945/9999999997-17-009945-index.htm